Ollie's had a mediocre quarter despite outperforming EPS and Same Store Sales estimates, as revenue missed and full-year guidance fell short. The company's stock fell 4.1% and future performance may be influenced by its valuation, business qualities, and recent results.
The market seems less excited about Ollie's Bargain Outlet Holdings than before, which could present an investment opportunity. The recent improvement in returns could suggest a positive shift within the business.
CEO notes strong closeout deal flow as consumers look to save on branded items, creating more opportunities. FY24 revenue estimated at $2.097B to $2.104B with an EPS of $2.77 to $2.83, outpacing consensus estimate.
CEO John Swygert expresses positive sentiments on Ms. Baglivo's appointment, stating that they're seeking to benefit from her extensive marketing and advertising experience and overall business acumen for executing their growth strategies and building the Ollie's brand.
Despite market incorporating OLLI's future growth, the stock appears steep due to high P/E ratio. Potential investors might find the current price prohibitive, while shareholders may consider selling, assuming stock should trade below current price due to high industry P/E ratio.
Q2 results impacted individual stocks with Ollie's, Nordstrom, Five Below, Dillard's, and Macy's witnessing a drop. Ollie’s improved outlook could lift its share price, while Nordstrom and Dillard's showed resilience. Macy's and Five Below's performance fell short, causing investor worry due to Macy's weaker annual guidance.
Gapping up $HPインク(HPQ.US)$+2.6% (JPMorgan upgraded computer builder to overweight from neutral, saying it expects the PC industry to see upward revisions for the second half of this year. JPMorgan also downgraded Dell to neutral from overweight, citing its preference for HP's expected recovery, as Dell's PC segment will likely be offset by other factors. ) $Prometheus Biosciences(RXDX.US)$+69% (The company will be acquired by$メルク(MRK.US)$for $10.8...
オリーズ・バーゲン・アウトレット・ホールディングスに関するコメント
コラムToday's Pre-Market Stock Movers: HPQ, GOOGL, WOLF, RXDX and More
$HPインク(HPQ.US)$ +2.6% (JPMorgan upgraded computer builder to overweight from neutral, saying it expects the PC industry to see upward revisions for the second half of this year. JPMorgan also downgraded Dell to neutral from overweight, citing its preference for HP's expected recovery, as Dell's PC segment will likely be offset by other factors. )
$Prometheus Biosciences(RXDX.US)$ +69% (The company will be acquired by $メルク(MRK.US)$ for $10.8...
コラムTop upgrades and downgrades on 6/27: ETSY, CHWY, BBBY, GTLB and more
• $オートゾーン(AZO.US)$ : Goldman Sachs Upgrades to Buy from Neutral - PT $2,296 (from $1,969)
• $チューイー(CHWY.US)$ : Needham Upgrades to Buy from Hold - PT $55
• $ナショナル・ビジョン・ホールディングス(EYE.US)$ : Goldman Sachs Upgrades to Buy from Neutral - PT $32 (from $31)
• $フレゼニウス・メディカル・ケア(FMS.US)$ : Jefferies Upgrades to Buy from Underperform - PT $33.70 (from $30.30)
• $ギットラブ(GTLB.US)$ : Goldman Sachs Upgrades to Buy from Neutral - ...
コラムToday's pre-market stock movers: NIO, NVAX, TSLA, SIG and more
• $シグネット・ジュエラーズ(SIG.US)$ +7.6% (In reaction to earnings/guidance)
• $オックスフォード・インダストリーズ(OXM.US)$ +6.3% (In reaction to earnings/guidance)
• $ブリッジバイオ・ファーマ(BBIO.US)$ +5%(to Present Phase 2b Data and Pivotal Phase 3 Study Design of Encaleret in Autosomal Dominant Hypocalcemia Type 1 (ADH1) at the Endocrine Society (ENDO) 2022 Annual Conference)
• $グライフ(GEF.US)$ +4.6% (In reaction to earnings/guidance)
• $オレマ・ファーマシューティカルズ(OLMA.US)$ +4.3% (an...
まだコメントはありません